Haier Biomedical Posts Record Overseas Growth as AI Strategy Advances
Haier Biomedical reported full-year 2025 revenue of 2.33 billion yuan (USD 340.77 million), with overseas revenue climbing 17.9% to 840 million yuan and now representing 36% of total sales - a company record. The Chinese life sciences equipment manufacturer delivered double-digit growth across all international regions despite a volatile trade environment.
The company has shifted from selling products abroad to building global brand presence. Asia-Pacific revenue grew 26%, while Europe increased 16%. Haier now operates subsidiaries in four countries and maintains localized operations in 18 others.
AI Revenue Reaches 15% of Total Business
AI-powered applications generated 15% of revenue in 2025, up from 12.5% the previous year. The company built what it calls a "multi-layer AI infrastructure" of large language models, AI agents, and AI terminals, developing 17 proprietary agents embedded in 13 automated solutions.
Its AI-powered pharmacy automation achieved an 80% direct dispensing rate - 1.1 times the industry average. A fully automated cell workstation won a Ministry of Industry and Information Technology award for disruptive technology, and a closed automated cell expansion system entered clinical trials for bioartificial liver applications.
New Business Segments Drive Revenue Mix
Smart medication systems, blood technology, and laboratory solutions contributed 48.5% of total revenue, up 8.8% year-over-year. These newer segments have become core growth engines alongside traditional biomedical freezer products.
Haier's ultra-low and low-temperature freezers hold first-place market share in six countries including Italy. The company also leads domestic competitors in export volume of smart medication dispensing solutions.
R&D Spending Increases 50% in Patent Filings
Haier invested 320 million yuan (USD 46.82 million) in research and development during 2025. New invention patents increased 50% to 1,620, and 11 solutions achieved industry-first status.
The company became the first in China to master stable 100,000-rpm ultra-high-speed centrifugation technology, addressing a technical bottleneck that strengthens its competitive position. Its plasma separation system became the first Chinese solution to receive EU MDR certification.
Strategic Targets Through 2028
Haier outlined three-year targets focused on three areas: overseas revenue exceeding 50% of total sales through localized operations; acquired businesses contributing at least 40% of future revenue; and AI-related revenue accounting for over 30%.
The company holds over 400 international product certifications and partners with nearly 80 international organizations including the WHO and UNICEF. Its distribution network spans more than 800 partners across 160 countries and regions.
For executives evaluating biomedical equipment suppliers or considering how AI reshapes operational strategy, Haier's approach offers a case study in how AI for Executives & Strategy can shift both revenue models and competitive positioning. The company's emphasis on Generative AI and LLM infrastructure as a business lever - rather than a feature - reflects how established industrial companies are reorganizing around AI capabilities.
Your membership also unlocks:
